타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111) bluebird bio·βA-T87Q-globin (lentiviral) 2 trials |
|---|---|
Overview Program | Lyfgenia (lovotibeglogene autotemcel) |
Overview Company | bluebird bio |
Overview Modality | CGT |
Overview Target | βA-T87Q-globin (lentiviral) |
Overview Indication | Sickle cell disease with recurrent vaso-occlusive events |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Gene addition of anti-sickling globin vs CRISPR HbF induction |
Positioning Known limitation | bypassing such limitations |
Technology Vector | Lentiviral vector |
MoA Mechanism | Lovotibeglogene autotemcel adds functional β-globin gene via lentiviral vector to autologous CD34+ cells, producing anti-sickling HbAT87Q in sickle cell disease. |
MoA Biomarker | HbAT87Q, VOC, TCD velocities. |
Toxicology Major finding | Hematologic malignancy risk (boxed warning); conditioning toxicities |
Clinical Safety signal | Hematologic malignancy risk (boxed warning); conditioning toxicities |
Clinical Program phase | APPROVED |
Clinical Trial activity | 1 recruiting · 1 completed |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111) bluebird bio·βA-T87Q-globin (lentiviral) 2 trials |
|---|---|
Overview Program | Lyfgenia (lovotibeglogene autotemcel) |
Overview Company | bluebird bio |
Overview Modality | CGT |
Overview Target | βA-T87Q-globin (lentiviral) |
Overview Indication | Sickle cell disease with recurrent vaso-occlusive events |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Gene addition of anti-sickling globin vs CRISPR HbF induction |
Positioning Known limitation | bypassing such limitations |
Technology Vector | Lentiviral vector |
MoA Mechanism | Lovotibeglogene autotemcel adds functional β-globin gene via lentiviral vector to autologous CD34+ cells, producing anti-sickling HbAT87Q in sickle cell disease. |
MoA Biomarker | HbAT87Q, VOC, TCD velocities. |
Toxicology Major finding | Hematologic malignancy risk (boxed warning); conditioning toxicities |
Clinical Safety signal | Hematologic malignancy risk (boxed warning); conditioning toxicities |
Clinical Program phase | APPROVED |
Clinical Trial activity | 1 recruiting · 1 completed |
추천 비교
추천 비교